- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Ruxolitinib Cream Maintains Atopic Dermatitis Control in Children Over 52 Weeks: Phase 3 TRuE-AD3 Trial

USA: Ruxolitinib cream demonstrated sustained disease control and a favourable safety profile over 52 weeks in children aged 2 to 11 years with mild-to-moderate atopic dermatitis (AD), findings from the Phase 3 TRuE-AD3 study. The results suggest that as-needed application of the topical Janus kinase (JAK) inhibitor may help maintain symptom control in children requiring long-term management of the inflammatory skin condition.
- Safety outcomes: Among 282 children receiving ruxolitinib cream during the long-term extension, no new safety concerns emerged. Application-site reactions were reported in 1.1% of participants.
- Treatment-related adverse events: No serious adverse events considered related to treatment were observed during the extension period.
- Disease control: Children initially assigned to ruxolitinib cream 0.75% and 1.5% maintained disease control through Week 52, with Investigator’s Global Assessment scores of 0 or 1 reported in 79.5% and 72.3% of patients, respectively.
- Affected skin area: The mean affected body surface area remained low at 2.0% with the 0.75% formulation and 1.9% with the 1.5% formulation, indicating sustained control of skin involvement.
MSc. Biotechnology
Medha Baranwal holds a Bachelor’s degree in Biomedical Sciences from the University of Delhi and a Master’s degree in Biotechnology from Amity University. Since May 2018, she has been contributing to Medical Dialogues, writing and editing medical news articles that translate complex research into clear, accessible information for healthcare professionals.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

